Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia

Lisa M. Niswander; Joseph P. Loftus; Élodie Lainey; Aurélie Caye-Eude; Morgane Pondrom; David A. Hottman; Ilaria Iacobucci; Charles G. Mullighan; Nitin Jain; Marina Konopleva; Hélène Cavé; André Baruchel; Pierre S. Rohrlich; Sarah K. Tasian

doi:10.3324/haematol.2021.278697

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia

Lisa M. Niswander, Joseph P. Loftus, Élodie Lainey, Aurélie Caye-Eude, Morgane Pondrom, David A. Hottman, Ilaria Iacobucci, Charles G. Mullighan, Nitin Jain, Marina Konopleva, Hélène Cavé, André Baruchel, Pierre S. Rohrlich, Sarah K. Tasian

Research output: Contribution to journal › Letter › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	2763-2767
Number of pages	5
Journal	Haematologica
Volume	106
Issue number	10
DOIs	https://doi.org/10.3324/haematol.2021.278697
State	Published - Oct 2021
Externally published	Yes

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2021.278697

Cite this

Niswander, L. M., Loftus, J. P., Lainey, É., Caye-Eude, A., Pondrom, M., Hottman, D. A., Iacobucci, I., Mullighan, C. G., Jain, N., Konopleva, M., Cavé, H., Baruchel, A., Rohrlich, P. S., & Tasian, S. K. (2021). Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica, 106(10), 2763-2767. https://doi.org/10.3324/haematol.2021.278697

Niswander, LM, Loftus, JP, Lainey, É, Caye-Eude, A, Pondrom, M, Hottman, DA, Iacobucci, I, Mullighan, CG, Jain, N, Konopleva, M, Cavé, H, Baruchel, A, Rohrlich, PS & Tasian, SK 2021, 'Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia', Haematologica, vol. 106, no. 10, pp. 2763-2767. https://doi.org/10.3324/haematol.2021.278697

@article{2b1c2438ece94c8ab514da42ded27c3e,

title = "Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia",

author = "Niswander, {Lisa M.} and Loftus, {Joseph P.} and {\'E}lodie Lainey and Aur{\'e}lie Caye-Eude and Morgane Pondrom and Hottman, {David A.} and Ilaria Iacobucci and Mullighan, {Charles G.} and Nitin Jain and Marina Konopleva and H{\'e}l{\`e}ne Cav{\'e} and Andr{\'e} Baruchel and Rohrlich, {Pierre S.} and Tasian, {Sarah K.}",

note = "Funding Information: Contributions: LMN analyzed and interpreted data and contributed to manuscript writing; JPL and DHA performed preclinical experiments and analyzed data; EL and AC-E performed clinical specimen assays, analyzed and interpreted data; MP provided clinical patient care and contributed to manuscript writing; II, CGM, NJ, and MK provided primary patient or PDX specimens and scientific input; HC and AB provided critical scientific advice and interpreted clinical genetic testing data; PSR and SKT conceived and directed the study, provided clinical patient care, analyzed and interpreted data, and wrote and/or edited the manuscript. All authors reviewed and approved the manuscript prior to submission. Acknowledgments: we gratefully acknowledge the Center for Biological Resources ({\textquoteleft}CRB-cancer{\textquoteright}) of the Robert Debr{\'e} Hospital (BB-0033-00076; EL, AC-E, and HC), Drs I-Ming Chen and Richard Harvey at the University of New Mexico for performing Ph-like ALL low density microarray expression analysis of primary clinical and patient-derived xenograft (PDX) model ALL specimens, Ms Elizabeth Wagner at Nationwide Children{\textquoteright}s Hospital for clinical annotation of COG ALL specimens, Dr Marilyn Li at CHOP for performing genetic characterisation of PDX models, and Dr Matthew Stubbs at Incyte Corporation for provision of ruxolitinib rodent chow for preclinical animal studies. We also kindly thank Dr Vandana Batra at the Children{\textquoteright}s Hospital of Philadelphia, Dr Jing Chen at Hackensack University Medical Center, and Dr Michael Loschi at CHU de Nice for assisting in clinical patient care. This study is dedicated in honor of Miss Emily Herrera and Miss Ava Daisy Phillips. Funding: these studies were supported by United States National Institutes of Health (NIH)/National Institute of Child Health and Human Development award T32HD043021 (LMN), NIH/National Cancer Institute (NCI) award T32CA009615 (LMN), 1U01CA232486 (SKT), U01CA243072 (SKT), the ERA-NET TRANSCAN/Foundation ARC (EL, AC-E, HC), Department of Defense Translational Team Science award CA180683P1, the V Foundation for Cancer Research (SKT), the Sohn Monaco Foundation (PSR), and the PHRC program from the French Institut National du Cancer (PSR). Children{\textquoteright}s Oncology Group (COG) specimen banking was supported by NCI U24CA114766 and U24CA196173. Childhood IGH-EPOR ALL PDX modeling was also supported by a Lady Tata Memorial Trust Award (II), St Jude Children{\textquoteright}s Research Hospital Hematological Malignancies Program Garwood Fellowship (II), Leukemia and Lymphoma Society Specialized Center of Research (CGM), Stand up to Cancer Innovative Research Grant (CGM), St Baldrick{\textquoteright}s Foundation Scholar award (CGM), NCI Outstanding Investigator Award R35CA197695 (CGM), and NIH Cancer Center Support Grant P30 CA21765 (CGM).",

year = "2021",

month = oct,

doi = "10.3324/haematol.2021.278697",

language = "English (US)",

volume = "106",

pages = "2763--2767",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "10",

}

TY - JOUR

T1 - Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia

AU - Niswander, Lisa M.

AU - Loftus, Joseph P.

AU - Lainey, Élodie

AU - Caye-Eude, Aurélie

AU - Pondrom, Morgane

AU - Hottman, David A.

AU - Iacobucci, Ilaria

AU - Mullighan, Charles G.

AU - Jain, Nitin

AU - Konopleva, Marina

AU - Cavé, Hélène

AU - Baruchel, André

AU - Rohrlich, Pierre S.

AU - Tasian, Sarah K.

N1 - Funding Information: Contributions: LMN analyzed and interpreted data and contributed to manuscript writing; JPL and DHA performed preclinical experiments and analyzed data; EL and AC-E performed clinical specimen assays, analyzed and interpreted data; MP provided clinical patient care and contributed to manuscript writing; II, CGM, NJ, and MK provided primary patient or PDX specimens and scientific input; HC and AB provided critical scientific advice and interpreted clinical genetic testing data; PSR and SKT conceived and directed the study, provided clinical patient care, analyzed and interpreted data, and wrote and/or edited the manuscript. All authors reviewed and approved the manuscript prior to submission. Acknowledgments: we gratefully acknowledge the Center for Biological Resources (‘CRB-cancer’) of the Robert Debré Hospital (BB-0033-00076; EL, AC-E, and HC), Drs I-Ming Chen and Richard Harvey at the University of New Mexico for performing Ph-like ALL low density microarray expression analysis of primary clinical and patient-derived xenograft (PDX) model ALL specimens, Ms Elizabeth Wagner at Nationwide Children’s Hospital for clinical annotation of COG ALL specimens, Dr Marilyn Li at CHOP for performing genetic characterisation of PDX models, and Dr Matthew Stubbs at Incyte Corporation for provision of ruxolitinib rodent chow for preclinical animal studies. We also kindly thank Dr Vandana Batra at the Children’s Hospital of Philadelphia, Dr Jing Chen at Hackensack University Medical Center, and Dr Michael Loschi at CHU de Nice for assisting in clinical patient care. This study is dedicated in honor of Miss Emily Herrera and Miss Ava Daisy Phillips. Funding: these studies were supported by United States National Institutes of Health (NIH)/National Institute of Child Health and Human Development award T32HD043021 (LMN), NIH/National Cancer Institute (NCI) award T32CA009615 (LMN), 1U01CA232486 (SKT), U01CA243072 (SKT), the ERA-NET TRANSCAN/Foundation ARC (EL, AC-E, HC), Department of Defense Translational Team Science award CA180683P1, the V Foundation for Cancer Research (SKT), the Sohn Monaco Foundation (PSR), and the PHRC program from the French Institut National du Cancer (PSR). Children’s Oncology Group (COG) specimen banking was supported by NCI U24CA114766 and U24CA196173. Childhood IGH-EPOR ALL PDX modeling was also supported by a Lady Tata Memorial Trust Award (II), St Jude Children’s Research Hospital Hematological Malignancies Program Garwood Fellowship (II), Leukemia and Lymphoma Society Specialized Center of Research (CGM), Stand up to Cancer Innovative Research Grant (CGM), St Baldrick’s Foundation Scholar award (CGM), NCI Outstanding Investigator Award R35CA197695 (CGM), and NIH Cancer Center Support Grant P30 CA21765 (CGM).

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85113300838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113300838&partnerID=8YFLogxK

U2 - 10.3324/haematol.2021.278697

DO - 10.3324/haematol.2021.278697

M3 - Letter

C2 - 34196168

AN - SCOPUS:85113300838

SN - 0390-6078

VL - 106

SP - 2763

EP - 2767

JO - Haematologica

JF - Haematologica

IS - 10

ER -

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this